Table 2.
Mean sitting BP reduction (mmHg) from baseline to week 26 by subgroups
| Subgroups | N | Aml/Val | ||
|---|---|---|---|---|
| Baseline msBP | msSBP | msDBP | ||
| Age, years | ||||
| <65 | 2209 | 163.9/100.7 | −34.3 (−34.95, −33.65) | −19.6 (−20.01, −19.20) |
| ≥65 | 275 | 168.0/99.1 | −36.3 (−38.50, −34.17) | −18.0 (−19.21, −16.82) |
| Sex | ||||
| Male | 1526 | 163.8/100.3 | −33.9 (−34.67, −33.06) | −18.8 (−19.34, −18.35) |
| Female | 968 | 165.0/100.9 | −35.4 (−36.38, −34.42) | −20.3 (−20.90, −19.71) |
| BMI, kg/m2 | ||||
| <30 | 1214 | 163.4/99.5 | −34.0 (−34.82, −33.09) | −18.5 (−19.03, −17.94) |
| ≥30 | 1159 | 164.9/101.5 | −34.5 (−35.45, −33.58) | −20.2 (−20.76, −19.64) |
| Diabetes mellitus | ||||
| Yes | 862 | 164.4/100.2 | −33.8 (−34.92, −32.64) | −19.3 (−19.95, −18.62) |
| No | 1633 | 164.2/100.6 | −34.8 (−35.58, −34.10) | −19.5 (−19.95, −19.01) |
| Baseline SBP, mmHg | ||||
| <140 | 41 | 127.7/89.0 | −3.7 (−6.82, −0.60) | −12.0 (−15.14, −8.96) |
| 140 to <160 | 607 | 148.8/97.6 | −22.1 (−22.86, −21.28) | −16.8 (−17.56, −16.06) |
| 160 to <180 | 1392 | 164.5/100.7 | −34.1 (−34.66, −33.62) | −19.4 (−19.91, −18.94) |
| ≥180 | 455 | 187.5/104.9 | −54.8 (−56.22, −53.41) | −23.5 (−24.44, −22.56) |
| ISH (SBP≥ 140 mmHg and DBP <90 mmHg) | ||||
| Yes | 90 | 158.1/80.6 | −27.8 (−30.67, −24.98) | −3.1 (−4.75, −1.47) |
| No | 2405 | 164.5/101.3 | −34.7 (−35.36, −34.09) | −20.0 (−20.39, −19.65) |
Data are mean (95 % confidence intervals)
Aml/Val amlodipine/valsartan, BMI body mass index, DBP diastolic blood pressure, ISH isolated systolic hypertension, msBP mean sitting blood pressure, msDBP mean sitting diastolic blood pressure, msSBP mean sitting systolic blood pressure, SBP systolic blood pressure